Wednesday, November 7, 2012

H Pylori: The silent killer living inside all of us


H Pylori: The silent killer living inside all of us


By Ritu Dokania, Friday magazine
Nov 7, 2012

It’s silent, insidious and is the cause of gastric symptoms that range from the antisocial to the downright dangerous. But why do so few people know of its existence? Ritu Dokania unveils the mysterious bacteria behind your most embarrassing symptoms...

Alisha, a 30-year-old sales manager, hated going out in public. She refused offers of evenings out with her friends, bypassed busy events and dreaded business meetings with a passion.
It wasn’t that she disliked socialising – she had always been quite gregarious at heart – but chronic gastric symptoms were making her life a misery and she preferred to hide herself away.
Although her symptoms were troublesome, ranging from bloating and mild stomach pain to flatulence and belching, they didn’t seem serious enough to seek medical advice. She did some research online and decided it could be aerophagia, which is caused by swallowing too much air, and tried to treat it by avoiding carbonated drinks and putting an end to her chewing gum and smoking habits. Yet nothing seemed to help.
Several months passed and Alisha was no longer just embarrassed by her symptoms, but was feeling uncomfortable throughout the entire day, while horrible abdominal cramps had started to keep her awake at night.She arranged an appointment with Dr Denesh Gopalan, a gastroenterologist at Welcare Hospital in Dubai. He decided to test her for the little-known bacteria, H Pylori. The diagnosis was positive.
“H Pylori is one of the most widespread infections in the world and around 60 per cent of the UAE population has it,” says Dr Gopalan. “Yet most people don’t know about this silent infection until they start suffering from gastritis or the painful effects of ulcers.”
Its presence is hard to detect, but delayed discovery can give rise to a number of problems as H Pylori is associated not only with ulcers, but also with stomach cancer and gastric malt lymphoma, which is a stomach cancer affecting the white blood cells of the immune system.
Thankfully, once the cause of Alisha’s problems had been pinpointed, her infection was easy to eradicate. “She was put on a course of antibiotics for 14 days, after which the symptoms she had been suffering from for so long subsided remarkably,” says Dr Gopalan.
H Pylori, short for Helicobacter Pylori, is a spiral-shaped bacterium that resides in the stomachs of humans and animals. Although our stomachs are lined with a protective coating to keep it safe from bacterial infections, H Pylori secretes an enzyme that neutralises stomach acid, enabling the bacteria to burrow deep into the walls of our stomachs, where it may survive undetected for decades.
The damage it causes to the mucous coating allows powerful stomach acid to get through to the sensitive lining beneath. Together, the stomach acid and H Pylori irritate the lining of the stomach or duodenum, which can cause ulcers and other complications.
The link between H Pylori and ulcers was a scientific breakthrough. Scientist Barry Marshall discovered it by deliberately ingesting broth infected with the bacteria in order to prove the connection, and in 2005 he and his colleague Robin Warren were awarded the Nobel Prize in Physiology or Medicine for their discovery, which reversed decades of doctrine that ulcers were caused by spicy food and stress.
The Centers for Disease Control and Prevention in Atlanta estimates that two-thirds of the world’s population is infected with the bacterium, making it the most widespread infection in the world.
It is most likely acquired by the ingestion of contaminated food or water, which can happen via faecal matter if food is prepared by people who do not wash their hands after using the bathroom, or in poor sanitary conditions. It can spread from person to person via saliva or by sharing food utensils and is most common in socio-economic groups characterised by crowded living conditions.
Symptoms and implications
H Pylori is often asymptomatic, meaning most people with the infection will never have any signs or symptoms. When symptoms do occur they may include burping, bloating, heartburn, oesophageal reflux, diarrhoea, constipation, flatulence and upper- and mid-abdominal pain. Difficulty losing weight may also be attributed to H Pylori, Dr Gopalan says. Having the infection causes stress and eventually cortisol.
H Pylori is also the leading cause of gastritis, an inflammation of the stomach lining. It is responsible for over 90 per cent of all duodenal ulcers and nearly 80 per cent of all gastric ulcers.
“This pernicious bacteria, which survives so easily in our stomachs, should be exterminated before it does serious harm,” says Dr Gopalan. “While it can remain in the human stomach for a long time without causing any symptoms, it may manifest into more serious diseases over time – one to two per cent of infected people are at risk of stomach cancer and the cancer gastric malt lymphoma is eight times more common in people with H Pylori than in those not infected.”
Apart from these diseases, medical researchers and doctors believe that H Pylori may be implicated in a number of non-digestive conditions including cardiovascular disorders, migraine and Raynaud’s disease (impaired circulation in the hands and feet). Surprisingly, it may also cause depression and anxiety. The happy chemical, serotonin, is largely seen in a healthy digestive system and damage to your stomach by H Pylori will lead to a shortage of this important chemical.

Detection, treatment and prevention

“When I tell my patients about this bacteria, seven out of ten of them will never have heard of it before,” says Dr Gopalan. “But I am more surprised to see that even physicians often do not think to test for this bacteria when a patient complains about the common symptoms of this infection.”

A patient’s breath can be a typical warning sign, says Dr Gopalan, as reflux directly from the stomach or higher levels of periodontal gum disease caused by the bacteria can give it a strong smell. Testing for H Pylori infection may be performed on blood, stool or breath samples or through biopsies of tissue from the lining of the gastrointestinal tract obtained during endoscopy.
H Pylori is successfully eradicated in 80 per cent of cases, but it can be a tough infection to treat, says Dr Gopalan, as it often resides in the deepest layers of the stomach. It is also important that the antibiotics are prescribed carefully.
“H Pylori quickly becomes resistant to several antibiotics when given one at a time,” says Dr Gopalan. For this reason, a ‘triple therapy’ is often employed, which consists of two types of antibiotics and a proton pump inhibitor (PPI), which is used to decrease the stomach’s acidity, allowing the inflamed stomach lining to heal. The treatment is given for ten to 14 days according to the presence and severity of the infection. After a month, the test is repeated to see if the infection has cleared.
“Some antibiotics that are recommended elsewhere in the world might not be suitable in UAE due to the bacteria’s resistance pattern here,” warns Dr Gopalan. “It is advisable to check with your doctor about whether the antibiotic prescribed is the correct one for your particular geographical area.”
Since the source of H Pylori is not yet fully known, recommendations for avoiding infection have not been made. In general, it is always wise to wash hands thoroughly, only eat food that has been hygienically prepared, and drink water from a safe, clean source.
Certain nutrients, especially vitamins A, C, and E, along with zinc, protect the stomach lining by combating free radicals, so ensure that you are not deficient in any of these. Certain probiotics (healthy bacteria) such as lactobacillus and bifidobacterium may also help protect you from H Pylori.

Saturday, November 3, 2012

A Case of Synchronous Lung Adenocarcinoma and Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type.


A Case of Synchronous Lung Adenocarcinoma and Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type.


July 2012

Source

Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.

Abstract


Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type (extranodal MZL) is a distinct subgroup of non-Hodgkin's lymphoma. Pulmonary extranodal MZL is a rare entity and accounts for less than 0.5% of primary pulmonary malignancies. Only a few cases of simultaneous occurrence of lung cancer and pulmonary extranodal MZL have been reported. A 60-year-old woman was referred to our hospital with a pulmonary nodule. She was diagnosed with lung adenocarcinoma by percutaneous needle biopsy. The protrusions into the left main bronchus were found by accident while performing bronchoscopy during lung cancer evaluation. The bronchial lesions were diagnosed as extranodal MZL. Although the patient underwent surgical resection for the lung adenocarcinoma, the pulmonary extranodal MZL was left untreated; it was monitored during follow-up visits. To our knowledge, this is the first report of synchronous lung adenocarcinoma and primary extranodal MZL of the main bronchus.

Tuesday, October 30, 2012

Marginal zone lymphoma of the thoracic dura causing spinal cord compression.


Marginal zone lymphoma of the thoracic dura causing spinal cord compression.


Sept 2012

Source

Section of Neurosurgery, Department of Surgery, University of Chicago Medical Center, Chicago, IL 60637, USA.

Abstract 


Primary extra-nodal marginal zone B cell lymphoma (Ex-MZBCL) or mucosa-associated lymphoid tissue (MALTlymphoma of the cranial dura is a rare but well-known entity. We describe a 58-year-old woman with primary MALT lymphoma of the spinal dura causing extreme thickening of the dura and spinal cord compression who initially presented with acute spinal cord compression from a chronic epidural lesion. She was treated with surgery and radiotherapy and diagnosed with a mature B-cell lymphoma based on gene rearrangement studies. Two years following the completion of radiotherapy, she presented with an increase in the size of the residual mass that was suggestive of an epidural lesion. On re-exploration, no epidural lesion was found; however, the dura was extremely thickened causing spinal cord compression. Clinical course, histological evaluation, immunostaining and gene rearrangement studies resulted in a final diagnosis of primary Ex-MZBCL of the spinal dura. To our knowledge, this is the first report of Ex-MZBCL in the spinal dura. This diagnosis should be considered when evaluating spinal cord lesions in patients with primary central nervous system (CNS) lymphoma, especially recurrent lesions, since this group of tumors carries a favorable outcome compared to other primary CNS lymphomas.

Simultaneous primary gastric and duodenal MALT lymphoma presenting with gastrointestinal bleeding.


Simultaneous primary gastric and duodenal MALT lymphoma presenting with gastrointestinal bleeding.


Jul 2012

Source

Units of Gastroenterology and Digestive Endoscopy, Pathologic Anatomy, Sandro Pertini Hospital; Unit of Gastroenterology, Sapienza University, Rome, Italy.

Abstract


The gastrointestinal tract, particularly the stomach, is the most common site of mucosa-associated lymphoid tissue lymphoma (MALToma). Many studies describe primary MALT lymphoma arising from the gastric mucosa, especially in association with Helicobacter pylori infection. On the contrary, primary MALT duodenal lymphoma is a very rare neoplasm. We report a case of a patient with gastrointestinal bleeding in whom primary gastric and duodenal MALT lymphoma were occurred simultaneously.

Complete Text La Clinica Terapeutica

Friday, October 26, 2012

Colonic mucosa-associated lymphoid tissue lymphoma.


Colonic mucosa-associated lymphoid tissue lymphoma.


May 2012

Source

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.

Abstract


Colonic mucosa-associated lymphoid tissue (MALT) lymphomas are rare and a definitive treatment has not been established. Solitary or multiple, elevated or polypoid lesions are the usual appearances of MALT lymphoma in the colon and sometimes the surface may reveal abnormal vascularity. In this paper we report our experience with four cases of colonic MALT lymphoma and review the relevant literature. The first patient had a smooth elevated lesion in the rectum and histopathologic examination of the biopsy from the lesion showed centrocyte-like cells infiltrating the lamina propria. Endoscopic ultrasonography (EUS) revealed thickening of the submucosa and muscularis propria. The patient underwent radiation therapy, and 9 months later a repeat colonoscopy showed complete resolution of the lesion. In case 2, colonoscopy showed a polyp in the cecum; the biopsy was diagnostic of MALT lymphoma. EUS detected a hypoechoic lesion confined to the mucosal layer of the colonic wall. The patient underwent endoscopic mucosal resection of the lesion and after 6 years of follow-up there was no evidence of recurrence. The third patient had a sessile elevated lesion in the sigmoid colon for which she underwent sigmoidectomy. Pathological examination of the surgical specimen was suggestive of MALT lymphoma. The last patient had a smooth elevated lesion in the rectum and magnification endoscopy showed irregular vascular pattern. The patient underwent endoscopic submucosal dissection, and biopsy examination showed the tumor to be MALT lymphoma. Although rare, awareness of MALT lymphoma of the colon is important to evaluate the patient appropriately and to plan further management.

Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.


Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.


Nov 2012

Source

Royal Marsden Hospital and the Institute of Cancer Research, Sutton, UK.

Abstract


Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy, with no standard treatment other than splenectomy. Rituximab has shown encouraging results. We therefore retrospectively assessed 43 patients from two centres, who received rituximab, either alone or with chemotherapy. All patients responded, 34/43 (79%) achieving a complete response (CR), compared with 3/10 (30%) after chemotherapy without rituximab (P = 0·005). Of these 10 patients, 9 (90%) subsequently achieved a CR after rituximab (P = 0·02). Rituximab monotherapy appeared equally as effective as rituximab combination therapy (90% vs. 79% CR, P = 0·7) with significantly less toxicity (12·5% vs. 83%, P = 0·002). Splenectomized patients were more likely to obtain a CR with rituximab (16/16, 100%) than unsplenectomized patients (18/27, 67%, P = 0·008). Disease-free survival (DFS) at 3 years was better after rituximab than after splenectomy alone [79% (95% confidence interval 60-89) vs. 29% (8-54), Hazard ratio (HR) 0·28 (0·12-0·68), P = 0·003] and better than after chemotherapy without rituximab [25% (4-55), HR 0·21 (0·08-0·51), P = 0·0004]. Survival at 3 years after rituximab was 98%. In summary, the CR and DFS rates after rituximab, given alone or with chemotherapy, were significantly better than after chemotherapy without rituximab in the same patients, with manageable toxicity. Rituximab, with or without splenectomy, should be considered for the treatment of SMZL

Saturday, October 20, 2012

Marginal Zone Lymphoma


Marginal Zone Lymphoma

Overview

Lymphoma is the most common blood cancer. The two main forms of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Lymphoma occurs when lymphocytes, a type of white blood cell, grow abnormally. The body has two main types of lymphocytes that can develop into lymphomas: B-lymphocytes (B-cells) and T-lymphocytes (T-cells). Cancerous lymphocytes can travel to many parts of the body, including the lymph nodes, spleen, bone marrow, blood or other organs, and can accumulate to form tumors.

Marginal zone lymphoma is a group of indolent (slow-growing) B-cell lymphomas, which account for approximately 12 percent of all B-cell lymphomas. The median age for diagnosis is 65.

Subtypes

There are three types of marginal zone lymphoma:

Extranodal marginal zone lymphoma of mucosa-associated lymphatic tissue (MALT) is the most common form of marginal zone lymphoma. It occurs outside the lymph nodes, such as the stomach, small intestine, salivary gland, thyroid, eyes and lungs. MALT is divided into two categories: gastric MALT, which develops in the stomach, and non-gastric MALT, which develops outside of the stomach. This form of lymphoma makes up approximately 9 percent of all B-cell lymphomas.

In many cases of MALT lymphoma, there is a previous medical history of inflammation or autoimmune disorders. For example, Helicobacter pylori (H. pylori), a microbial pathogen linked to chronic gastritis, has been associated with a significant portion of gastric MALT patients.

Nodal marginal zone lymphoma (sometimes called monocytoid B-cell lymphoma) occurs within the lymph nodes and makes up approximately 2 percent of all B-cell lymphomas.

Splenic marginal zone lymphoma occurs mostly in the spleen and blood. It has been associated with Hepatitis C. This form of lymphoma makes up approximately 1 percent of all B-cell lymphomas. 

See Complete Page and please support:  Lymphoma Research Foundation